
(3 Minutes Read)
The joint venture structure grants the Egyptian side a 40 per cent share, while Dawah Pharma holds a 60% majority stake. The newly formed company will focus primarily on exporting its products and opening new channels in global markets.
The Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies has entered into a strategic joint venture with American pharmaceutical firm Dawah Pharma. This partnership marks a significant step in Egypt’s push to expand its pharmaceutical footprint globally, with plans to manufacture and export a broad range of pharmaceutical products and dietary supplements to international markets.
Minister of Public Business Sector Mohamed Shimi announced that the new venture will produce a diverse portfolio of products, including ampoules, sterile injections, ophthalmic solutions, over-the-counter (OTC) medications, and dietary supplements.
The joint venture structure grants the Egyptian side a 40 per cent share, while Dawah Pharma holds a 60% majority stake. The newly formed company will focus primarily on exporting its products and opening new channels in global markets.
Read Also:
https://trendsnafrica.com/egypt-to-unveil-a-comprehensive-investment-plan-for-more-fdi/
In a milestone move, the partnership’s first phase will see the manufacture and export of six specific dietary supplements to the United States, marking the first time in the Holding Company’s history to achieve such a feat after meeting rigorous international standards and requirements.